|Bid||2.6900 x 800|
|Ask||2.7000 x 3100|
|Day's Range||2.6500 - 2.7300|
|52 Week Range||2.3500 - 5.4000|
|Beta (3Y Monthly)||1.97|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jan 20, 2020 - Jan 24, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.88|
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]
SUNNYVALE, California, Nov. 7, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) – Thailand's Lopburi Cancer Hospital, a center of excellence for cancer treatment, is the first in the Asia-Pacific region to clinically use the combination of RaySearch's treatment planning system RayStation® with Accuray's Radixact® Treatment Delivery System. Lopburi has a focus on innovation and has been designated a national center of excellence for cancer treatment.
SUNNYVALE, Calif. , Nov. 6, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Stock Market Rules, equity inducement awards to Suzanne Winter , the company's ...
Accuray (ARAY) delivered earnings and revenue surprises of -10.00% and -4.03%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
SUNNYVALE, Calif. , Oct. 29, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the first quarter of fiscal 2020 ended September 30, 2019 . Recent Company ...
SUNNYVALE, Calif., Oct. 21, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that Suzanne Winter has joined the company as Senior Vice President, Chief Commercial Officer effective October 21, 2019. Ms. Winter will have global responsibility for the commercial function reporting to Accuray's President and CEO, Joshua Levine. Ms. Winter has more than 25 years of medical technology experience in senior executive roles spanning general management, commercial operations, and strategic business development across a range of healthcare industry segments, including radiology, neurology and surgery.
SUNNYVALE, Calif. , Oct. 10, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its first quarter ended September 30, 2019 on Tuesday, October 29, 2019 after the market close. ...
SUNNYVALE, Calif., Sept. 19, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) today published an informational guide designed to help radiation oncology practices understand the complexities of the much-anticipated proposed Medicare & Medicaid reimbursement changes. Titled, "Thriving Under the Radiation Oncology Alternative Payment Model: A Definitive Guide to a New Reality," the guide aims to help radiation oncology professionals understand the changes outlined in the Radiation Oncology – Alternative Payment Model (RO-APM). "We believe that the proposed alternative payment model will reshape economic realities and evolve clinical best practices for radiation oncologists," said Joshua H. Levine, President and Chief Executive Officer of Accuray.
SUNNYVALE, Calif., Sept. 17, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) announces that The Lancet Oncology, a high impact and leading global peer-reviewed oncology journal, has published patient- and clinician-reported outcomes data from the PACE — Prostate Advances in Comparative Evidence — trial in its most recent issue. While further investigation is planned, data reported in the journal indicate that the level of grade 2 or higher acute genitourinary toxicity in the stereotactic body radiation therapy (SBRT) arm of the trial is lower for patients treated with the Accuray CyberKnife® System than it is for patients treated on a conventional linear accelerator. SBRT involves the delivery of very high doses of externally-administered radiation over a small number of treatment sessions, offering convenience for patients, compared to conventional radiation therapy which requires a substantially longer course of treatment.
SUNNYVALE, Calif., Sept. 16, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) announced that, on September 11, 2019, China's Customs Tariff Commission of the State Council issued a tariff exemption for medical linear accelerators. The tariff exemption, which will be effective September 17, 2019 and is scheduled to last for one year, applies to the additional tariffs China imposed on U.S. products effective as of August 23, 2018. Accuray expects to benefit from such tariff exemption. "We applaud the recent decision to exempt medical linear accelerators," said Josh Levine, president and chief executive officer, Accuray.
SUNNYVALE, Calif., Sept. 12, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) strengthened its Board of Directors with the appointment of James (Jim) M. Hindman, effective as of September 6, 2019, and expanding the company's Board to nine members. Mr. Hindman, an experienced healthcare executive with a 30-year tenure at Allergan, Inc., is an accomplished financial executive with expertise in maximizing shareholder value. Mr. Hindman will serve on the Board's Audit Committee.
SUNNYVALE, Calif., Sept. 10, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that the Geisinger Medical Center radiation oncology team is first in Pennsylvania to treat cancer patients with the innovative Radixact® System. The hospital, located in Danville, is part of Geisinger Health System, one of the United States' most innovative health services organizations. The system's speed, versatility and flexibility will enable the clinical team to provide a treatment option for virtually any case for which radiation therapy is prescribed, including large tumors or multiple tumors throughout the body, hard-to-reach tumors, and tumors that have recurred, including those in patients who may not be candidates for retreatment with traditional delivery systems.